APT Medical Inc (688617) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of APT Medical Inc stock ¥254, price ¥285, that is 10.9% below the price, quality 78 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range ¥67.58 – ¥330.49 · fair‑value band ¥149.98 – ¥418.68 · the ¥285.26 price screens above the ¥254.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow APT Medical in your weekly email
Every Wednesday you see whether APT Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
APT Medical Inc. engages in the research and development, production, and sale of cardiovascular interventional medical devices in China.
Show moreShow less
It offers electrophysiology products, such as navigation systems, navigated catheters, mapping catheters, ablation catheters, transseptal needles and sheaths, and steerable sheaths; and interventional cardiology and peripheral products, including access, diagnostic products, therapeutic products, and accessories.
The company also manufactures and supplies EP and vascular intervention medical devices.
In addition, it provides OEM and ODM services comprising project design and development, customization, and volume OEM; and customized products consisting of catheters, guidewires, and delivery systems, as well as nitinol products in cardiology, peripheral, neurology, and urology.
APT Medical Inc. was founded in 2002 and is headquartered in Shenzhen, China.
Stock analysis
APT Medical Inc (688617) currently trades at ¥285.26, while our model-based Fair Value estimate is ¥254.06, 11% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥258.91 per share, and 0 of the 26 models we run sit above the ¥285.26 price.
Bear case: the Economic Profit group reads lowest at ¥73.51, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥149.98 (bear) to ¥418.68 (bull), the price of ¥285.26 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 78/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
APT Medical Inc reported revenue of 2.6B CNY in FY2025 versus 829M CNY in FY2021, a compound +32.9%/yr. Reported net income was 821M CNY in FY2025, compounding +40.9%/yr from FY2021.
Key figures
Market cap 40.2B CNY (≈ $6.0B) Mid · P/E ratio 43.2 · P/S ratio 13.9 · EPS (TTM) ¥6.61 · Dividend yield 0.4% · Net margin 32.2% · Return on equity 30.8% · Return on assets (EBIT) 20.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 92 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 57% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −11%, 688617 screens cheaper than that median.
Fair Value models
Bear¥149.98Fair Value ¥254.06Bull¥418.68
Price ¥285.26 · Downside -10.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥4.80 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+25.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+43.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+42.8%
Dividend (yield on the price)0.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 37%
2025 sits 55% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +29.2% a year for the price and +19.4% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score78 · Top 25%
Fair Value upside−10.9% · Above median
Profitability
Return on equity (12 months)30.8% · Top 25%
Return on assets22.5% · Top 25%
Net margin (12 months)32.2% · Top 25%
Operating margin (12 months)39.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)26.6% · Top 25%
Dividend yield (12 months)0.4% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "APT Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/688617
Frequently asked questions
Is APT Medical Inc (688617) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥254.06 versus a price of ¥285.26, about 11% lower (overvalued).
What is the fair value of 688617?
Our model-based fair value for APT Medical Inc is ¥254.06 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥285.26.
What is the quality score of 688617?
APT Medical Inc has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for APT Medical Inc (688617)?
Our model-based price target is the fair value of ¥254.06 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario ¥149.98, optimistic scenario ¥418.68. It is a calculation from audited fundamentals, not an analyst target.
What is the APT Medical Inc stock forecast for 2026?
Our models put fair value at ¥254.06, about 11% lower versus a price of ¥285.26 (overvalued). Cautious scenario ¥149.98, optimistic scenario ¥418.68. The calculation is refreshed regularly with new filings.
What is the revenue of APT Medical Inc (688617)?
APT Medical Inc reported trailing-twelve-month revenue of about 2.9B CNY (latest available figure, as of Nov 6, 2026).
Does APT Medical Inc pay a dividend?
APT Medical Inc currently shows a dividend yield of 0.35% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of APT Medical Inc (688617) and when is the ex-dividend date?
APT Medical Inc pays a dividend of ¥1.00 per share a year, a dividend yield of 0.4%. The last ex-dividend date was May 14, 2026. A dividend has been paid every year since at least 2021. The payout ratio is 15.1% of earnings. Free cash flow covers the dividend 4.87 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into APT Medical Inc (688617)?
For today's price to be fair in a discounted-cash-flow model, APT Medical Inc would have to grow free cash flow by +31.4 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +40.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of 688617 use?
Our models discount APT Medical Inc at 10.4 %: a base by market capitalisation (mid), country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For APT Medical Inc that is +31.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has APT Medical Inc (688617) delivered so far?
Over the past 5 years revenue at APT Medical Inc grew +40.1 % a year. The price currently implies free-cash-flow growth of +31.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of APT Medical Inc (688617) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into APT Medical Inc (+31.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of APT Medical Inc (688617)?
The free-cash-flow yield on the price is 1.71 %: that much free cash flow APT Medical Inc produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of APT Medical Inc (688617)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For APT Medical Inc it is ¥254.06 per share (as of Nov 6, 2026), against a price of ¥285.26. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is APT Medical Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 688617 trades above its calculated fair value: price ¥285.26, fair value ¥254.06, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688617?
No. The price is what the market pays today (¥285.26); the fair value is what the company's own numbers justify (¥254.06). For APT Medical Inc the two are ¥31.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is APT Medical Inc worth?
The market values APT Medical Inc at about 40.2B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥285.26; our models calculate a fair value of ¥254.06 per share.
What do the bullish and bearish scenarios say about 688617?
Our models span a range for APT Medical Inc: cautious scenario ¥149.98, base ¥254.06, optimistic ¥418.68 per share (as of Nov 6, 2026, price ¥285.26). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688617?
APT Medical Inc trades at a price-to-earnings ratio of 43.2 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥254.06 is built from several models across several years. Other multiples: P/B 13.0, P/S 13.9, EV/EBITDA 34.9.
How solid is the balance sheet of APT Medical Inc (688617)?
Balance-sheet figures for APT Medical Inc (as of Nov 6, 2026): return on equity 30.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is 688617 from its 52-week high?
APT Medical Inc trades at ¥285.26, at its 52-week high of ¥285.26 and 57% above the low of ¥181.27 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥254.06 is for.
Which stocks are comparable to APT Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is APT Medical Inc stock attractive at the current price?
The data as of Nov 6, 2026: price ¥285.26, calculated fair value ¥254.06 (−11%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688617 calculated?
We run APT Medical Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥254.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. APT Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of APT Medical Inc (688617)?
The closing price on Nov 6, 2026 was ¥285.26. Our model-based fair value is ¥254.06, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with APT Medical Inc right now?
The model range is unusually wide (¥149.98 to ¥418.68). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Key figures of APT Medical Inc
How large is the market capitalisation of APT Medical Inc (688617)?
The market capitalisation of APT Medical Inc is 40.2B CNY (≈ $6.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of APT Medical Inc (688617)?
The price-to-sales ratio of APT Medical Inc is 13.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of APT Medical Inc (688617)?
Earnings per share at APT Medical Inc are ¥6.61 (price ÷ EPS = P/E 43.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of APT Medical Inc (688617)?
The dividend yield of APT Medical Inc is 0.4% (payout 15.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of APT Medical Inc (688617)?
The net margin of APT Medical Inc is 32.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of APT Medical Inc (688617)?
The return on equity (ROE) of APT Medical Inc is 30.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of APT Medical Inc (688617)?
On an EBIT basis the return on assets of APT Medical Inc is 20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of APT Medical Inc (688617)?
The operating margin of APT Medical Inc is 39.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at APT Medical Inc (688617)?
Revenue at APT Medical Inc is growing +26.6% versus a year earlier (3y avg +28.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at APT Medical Inc (688617)?
Earnings per share at APT Medical Inc are growing +27.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does APT Medical Inc (688617) hold?
APT Medical Inc holds more cash than debt, 1.2B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch APT Medical Inc in the live analysis
One click puts APT Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026